Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rossari Biotech's Other Operating Expense for the
three
months ended in Jun. 2026 was ₹1,514 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was ₹5,500 Mil.
Rossari Biotech's quarterly Other Operating Expense
increased
from Dec. 2025 (₹1,316 Mil) to Mar. 2026 (₹1,354 Mil) and
increased
from Mar. 2026 (₹1,354 Mil) to Jun. 2026 (₹1,514 Mil).
Rossari Biotech's annual Other Operating Expense
increased
from Mar. 2024 (₹2,571 Mil) to Mar. 2025 (₹3,117 Mil) and
increased
from Mar. 2025 (₹3,117 Mil) to Mar. 2026 (₹3,774 Mil).
Rossari Biotech Other Operating Expense Related Terms
Rossari Biotech Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Rossari Biotech's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹5,500 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of ₹5,500 Mil mean?
Rossari Biotech (NSE:ROSSARI) has a Other Operating Expense of ₹5,500 Mil as of Jun. 2026. Other operating expenses that a company records on its income statement. View historical data on Rossari Biotech and its competitors.
Is Rossari Biotech's Other Operating Expense too high?
Rossari Biotech's current Other Operating Expense is ₹5,500 Mil. Overall, Rossari Biotech has a GF Score™ of 84/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Rossari Biotech's Other Operating Expense compare to LIN and SHW?
Rossari Biotech's Other Operating Expense of ₹5,500 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Chemicals company?
A good Other Operating Expense depends on the Chemicals industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Rossari Biotech and its competitors. Rossari Biotech's current Other Operating Expense is ₹5,500 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rossari Biotech stock overvalued right now?
Based on GuruFocus' analysis, Rossari Biotech (NSE:ROSSARI) is currently considered Possible Value Trap. The stock's GF Value™ is ₹966.72, compared to a current price of ₹504.30 — trading 47.8% below its estimated fair value. The current Other Operating Expense is ₹5,500 Mil. Rossari Biotech's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Rossari Biotech (NSE:ROSSARI), the current Other Operating Expense is ₹5,500 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rossari Biotech (NSE:ROSSARI) Overvalued in 2026?
Based on GuruFocus' analysis, Rossari Biotech stock appears to be undervalued.
The current stock price of ₹504.30 is trading 47.8% below its estimated GF Value™ of ₹966.72.
GuruFocus considers Rossari Biotech to be Possible Value Trap.
Key valuation signals for NSE:ROSSARI:
Other Operating Expense: ₹5,500 Mil
GF Value™: ₹966.72 vs. price of ₹504.30 (47.8% below fair value)
No single metric tells the full story. See the NSE:ROSSARI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rossari Biotech Ltd is a specialty chemical manufacturing company. It provides customized solutions to specific industrial and production requirements of its customers in the FMCG, apparel, poultry, and animal feed industries through its product portfolio comprising home, personal care, and performance chemicals; textile specialty chemicals; and animal health and nutrition products. Its business is organized into three categories: home, personal care, and performance chemicals; textile specialty chemicals; and animal health and nutrition products. Its products include soaps and detergents, paints, inks and coatings, ceramics and tiles, water treatment chemicals, pulp and paper, and cleaning chemical formulations, among others. The company generates the majority revenue from India.
84GF Score
Get the complete analysis for NSE:ROSSARI
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ROSSARI has been successfully added to your 
